The ACME Laboratories Ltd. announcements
156 Dhaka Stock Exchange announcements for The ACME Laboratories Ltd. (ACMELAB) since 2016: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2023 (16).
- Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AA\" in the long term and
Credit Rating Information and Services Limited (CRISL) has assigned rating of the Company as \"AA\" in the long term and \"ST-2\" for short term along with Positive outlook in consideration of its audited financials up to June 30, 2023 also unaudited financials up to September 30, 2023 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
- Resumption after Record Date
Trading of the shares of the company will resume on 23.11.2023.
- Suspension for record date
Trading of the shares of the company will remain suspended on record date i.e., 22.11.2023.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 20.11.2023 to 21.11.2023 and trading of the shares will remain suspended on record date i.e., 22.11.2023.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 3.11 for July-September 2023 as against Tk. 2.93 for July-September 2022; NOCFPS was Tk. 2.93 for July-September 2023 as against Tk. 2.52 for July-September 2022. NAV per share was Tk. 113.20 as on September 30, 2023 and Tk. 110.09 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2023.
- Appointment of Company Secretary
The Company has informed that the Board of Directors has appointed Mr. Masudur Rahman Bhuyian, FCS as the Company Secretary of the company with effect from the date of joining, i.e. August 17, 2023.
- Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2023) following its corporate declaration. However, the floor price shall be applicable accordingly.
- Dividend Declaration
The Board of Directors has recommended 33% cash dividend for the year ended June 30, 2023. Date of AGM: 18.12.2023, Time: 11:30 AM, Venue: Digital Platform. Record Date: 22.11.2023. The Company has also reported EPS of Tk. 10.89, NAV per share of Tk. 110.09 and NOCFPS of Tk. 5.95 for the year ended June 30, 2023 as against Tk. 9.98, Tk. 102.50 and Tk. 5.37 respectively for the year ended June 30, 2022.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 26, 2023 at 5:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2023.
- The company has informed that their product \"Chlorzoxazone 500 mg tablet\" which was manufactured from Solid Dosage Uni
The company has informed that their product \"Chlorzoxazone 500 mg tablet\" which was manufactured from Solid Dosage Unit (SDU-Unit 2) of The ACME Laboratories Ltd. and submitted to US FDA, has been approved by US Food & Drug Administration (US FDA) as per the section 505 (j) of the Federal Food, Drug and Cosmetic Act (FD&C ACT). The company has also informed that this prestigious accreditation will enable them to export products to the US market.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 2.53 for January-March 2023 as against Tk. 2.38 for January-March 2022; EPS was Tk. 7.98 for July 2022-March 2023 as against Tk. 7.55 for July 2021-March 2022. NOCFPS was Tk. 6.82 for July 2022-March 2023 as against Tk. 5.35 for July 2021-March 2022. NAV per share was Tk. 107.48 as on March 31, 2023 and Tk. 102.50 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 26, 2023 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2023.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 2.52 for October-December, 2022 as against Tk. 2.40 for October-December, 2021; EPS was Tk. 5.45 for July-December, 2022 as against Tk. 5.17 for July-December, 2021. NOCFPS was Tk. 6.09 for July-December, 2022 as against Tk. 7.19 for July-December, 2021. NAV per share was Tk. 104.95 as on December 31, 2022 and Tk. 102.50 as on June 30, 2022.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2023 at 4:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2022.
- Dividend Disbursement
The Company has informed that it has disbursed the cash dividend for the year ended June 30, 2022 to the respective shareholders.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.